Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2016-05-25 Earnings Release
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA)
Earnings Release Classification · 95% confidence The document is a press release dated May 24, 2016, announcing the successful completion of End-of-Phase 2 FDA and EMA consultations regarding rheumatoid arthritis (RA) studies for a drug named filgotinib. It details upcoming Phase 3 study plans (FINCH program), dosing, and collaboration updates with Gilead. This type of announcement, focusing on clinical trial milestones, regulatory interactions, and immediate business updates outside of routine financial reporting (like 10-K or IR), is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it provides key operational and clinical highlights immediately following regulatory discussions, it fits best as an Earnings Release (ER) which often includes significant operational news alongside or instead of quarterly financials, or potentially a Regulatory Filing (RNS) if it were less comprehensive. Given the structure and focus on key operational achievements and future plans, ER is a strong candidate, but since it is not explicitly labeled as an 'Earnings Release' and is more of a general corporate update on R&D progress, it could also be classified as a Regulatory Filing (RNS) if it doesn't fit other specific categories. However, press releases detailing major clinical/regulatory milestones are frequently categorized as ERs when they are the primary communication vehicle for such news. Given the options, and the fact that it is a time-sensitive announcement of significant corporate/pipeline progress, ER is the most appropriate fit over the general RNS fallback, as it communicates key performance indicators (milestones achieved). The document length (6036 chars) is substantial enough to be more than just a brief announcement of a report being available (RPA). Q2 2016
2016-05-25 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of May 2016. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F, often including press releases or other announcements. The document references an attached press release (Exhibit 99.1) but does not contain detailed financial statements or substantive financial data itself. The document length is short (1482 characters), and it primarily serves as a regulatory filing to report the press release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full report or financial statement.
2016-05-25 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of May 2016. It references a press release attached as Exhibit 99.1 but does not contain substantive financial data or detailed report content itself. The document length is short (1482 characters), and it primarily serves as a regulatory filing to report the press release. According to the rules, such filings that are brief and serve as notices or attachments without full report content should be classified as Regulatory Filings (RNS).
2016-05-25 English
Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA)
Earnings Release Classification · 95% confidence The document is a press release dated May 24, 2016, announcing the successful completion of End-of-Phase 2 FDA and EMA consultations regarding rheumatoid arthritis (RA) studies for a drug named filgotinib. It details upcoming Phase 3 study plans (FINCH program), dosing, and collaboration updates with Gilead. This type of announcement, focusing on clinical trial milestones, regulatory interactions, and immediate business updates outside of routine financial reporting (like 10-K or IR), is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it provides key operational and clinical highlights immediately following regulatory discussions, it fits best as an Earnings Release (ER) which often includes significant operational news alongside or instead of quarterly financials, or potentially a Regulatory Filing (RNS) if it were less comprehensive. Given the structure and focus on key operational achievements and future plans, ER is a strong candidate, but since it is not explicitly labeled as an 'Earnings Release' and is more of a general corporate update on R&D progress, it could also be classified as a Regulatory Filing (RNS) if it doesn't fit other specific categories. However, press releases detailing major clinical/regulatory milestones are frequently categorized as ERs when they are the primary communication vehicle for such news. Given the options, and the fact that it is a time-sensitive announcement of significant corporate/pipeline progress, ER is the most appropriate fit over the general RNS fallback, as it communicates key performance indicators (milestones achieved). The document length (6036 chars) is substantial enough to be more than just a brief announcement of a report being available (RPA). Q2 2016
2016-05-24 English
Succesvolle afronding Eind Fase 2 overleg met FDA en EMA voor reuma
Regulatory Filings Classification · 95% confidence The document is dated May 24, 2016, and is titled with a headline announcing the successful completion of discussions with the FDA and EMA regarding a drug (filgotinib) and the start of Phase 3 studies. It contains contact information for Investors and Media, and a standard section on 'Toekomstgerichte verklaringen' (Forward-looking statements) which explicitly mentions filings with the U.S. Securities and Exchange Commission (SEC), including the most recent Form 20-F. The content is a press release announcing clinical trial progress and regulatory milestones, not a full financial report (10-K or IR) or a transcript (CT). This type of announcement, detailing key operational and regulatory updates, most closely aligns with an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's a broad announcement. However, given the focus on clinical trial updates and regulatory interactions, it functions as a significant corporate update. Since it is a formal announcement of material information (FDA/EMA feedback, Phase 3 start) released to the public, and it is not a specific financial report, dividend notice, or management change, it fits best under the general category for significant regulatory/corporate announcements that aren't explicitly defined elsewhere. In the context of financial databases, such press releases often fall under 'Regulatory Filings' (RNS) or sometimes 'Earnings Release' (ER) if released concurrently with results. Since this is purely a clinical/regulatory update, RNS is the most appropriate fallback for a non-standard announcement, although it shares characteristics with an ER in its format. Given the strong emphasis on regulatory milestones and the press release format, RNS is selected as the best fit among the provided options for a general, material corporate announcement.
2016-05-24 Dutch
Galapagos increases share capital through warrant exercises
Share Issue/Capital Change Classification · 99% confidence The document is a formal announcement dated May 19, 2016, titled "Galapagos verhoogt kapitaal door uitoefening van warrants" (Galapagos increases capital through the exercise of warrants). It explicitly details the issuance of new shares resulting from the exercise of warrants by management and directors, leading to an increase in the company's share capital and total number of voting rights. This content directly relates to changes in the company's capital structure and financing activities. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV).
2016-05-20 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.